Medical device company Artivion (NYSE:AORT) reported Q1 CY2025 results , with sales up 1.6% year on year to $98.98 million.

Doctors at IPGMER successfully performed a rare stent grafting procedure on a 66-year-old aortic dissection patient. Due to a narrow femoral artery, the traditional groin access was not feasible.

Artivion presents new clinical data from NEXUS TRIOMPHE IDE trial at the 105th AATS Annual Meeting: Atlanta Tuesday, May 6, 2025, 13:00 Hrs [IST] Artivion, Inc., a leading cardiac ...

Endospan announced 30-day results of the statistical Dissection primary arm from the TRIOMPHE investigational device ...

The Nexus aortic arch stent graft system is made of nitinol and polyester. [Image from Endospan] Endospan today announced the presentation of 30-day results from a study evaluating its Nexus ...

TEL AVIV, Israel — Endospan today announced the presentation of 30-day results of the statistical Dissection Primary Arm from the TRIOMPHE Investigational Device Exemption (IDE) clinical study ...

clinical study evaluating the NEXUS® Aortic Arch Stent-Graft System. The data were presented during the late-breaking trial session at the American Association for Thoracic Surgery (AATS ...

TEL AVIV, Israel--(BUSINESS WIRE)-- Endospan today announced the presentation of 30-day results of the statistical Dissection Primary Arm from the TRIOMPHE Investigational Device Exemption (IDE) ...

Endospan today announced the presentation of 30-day results of the statistical Dissection Primary Arm from the TRIOMPHE Investigational Device Exemption (IDE) clinical study evaluating the NEXUS® ...